The stock’s performance has been below most large drugmakers’ performance. Biogen's revenues declined 3% in the first nine months of 2024. Sales of Biogen’s key multiple sclerosis (“MS ...

Sustainalytics’ Controversies Research identifies companies involved in incidents and events that may negatively impact stakeholders, the environment or the company’s operations. Controversies ...

Biogen (BIIB) stock slipped as Piper Sandler downgraded the company to neutral from overweight, citing challenges in Alzheimer's drug market. Read more here.

Biogen's stock underperformed in 2024 due to poor sales of Leqembi and declining multiple sclerosis revenues, despite efforts to diversify its pipeline. Leqembi's market struggles continue ...

Biogen Inc. closed $118.40 short of its 52-week high ($268.30), which the company achieved on January 3rd.

Biogen Inc. closed $119.28 below its 52-week high ($268.30), which the company reached on January 3rd.

Investors in Biogen Inc (Symbol: BIIB) saw new options become available this week, for the February 2025 expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the ...

Biogen BIIB stock has declined 21.4% in the past three months against a decrease of 12.3% for the industry. The stock has also underperformed the sector and the S&P 500 index, as seen in the chart ...